Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes

Table 3

Post-hoc Analysis of Patients with Documented Incident Infection—Results from the First Treatment Period.

	HSV-2 Antibody	HSV-2 Antibody
	Negative^a𝑛=4	Positive 𝑛=31
Percent days with total shedding, Mean (SD %)  𝑃-value^b	43.8 (18.6 )	11.2 (14.8)
	𝑃<.001
Percent days with subclinical shedding, Mean (SD %)  𝑃-value^b	31.9 (12.8 )	8.9 (14.1)
	𝑃=.002
Proportion of subjects recurrence-free^c, 𝑛 (%)	0 (0)	19 (61)

^aThis group includes 3 subjects who were HSV-1 and HSV-2 seronegative, and one subject who was HSV-1 seropositive and HSV-2 seronegative. ^bThis was an exploratory analysis; 𝑃-values should be regarded only as a rough guide to the magnitude of differences between groups. ^cThis difference was statistically significant (𝑃=.04); however, this was an exploratory analysis.